(NASDAQ: HOTH) Hoth Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 37.26%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 41%.
Hoth Therapeutics's earnings in 2025 is -$10,190,355.On average, 3 Wall Street analysts forecast HOTH's earnings for 2025 to be -$7,032,588, with the lowest HOTH earnings forecast at -$6,756,800, and the highest HOTH earnings forecast at -$7,239,429. On average, 3 Wall Street analysts forecast HOTH's earnings for 2026 to be -$7,979,282, with the lowest HOTH earnings forecast at -$7,666,369, and the highest HOTH earnings forecast at -$8,213,967.
In 2027, HOTH is forecast to generate -$9,466,945 in earnings, with the lowest earnings forecast at -$9,095,693 and the highest earnings forecast at -$9,745,385.